Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PTPRB | P23467 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872106 | 0.84 | PPARG (0.40) | ESR1ESR2PTPRBPPARGPPARD | |
| SCHEMBL5871796 | 0.83 | PPARG (0.39) | PTPRBPPARGPPARDPPARAACHE | |
| SCHEMBL5872194 | 0.83 | ACHE (0.39) | PTPRBPPARGPPARDPPARAACHE | |
| SCHEMBL5871435 | 0.80 | PTPRB (0.38) | PTPRBPPARGPPARDPPARA | |
| SCHEMBL5872069 | 0.78 | PTPRB (0.43) | ESR1ESR2PTPRBPPARGPPARD | |
| SCHEMBL5872007 | 0.77 | MAPT (0.40) | — | |
| SCHEMBL5872159 | 0.75 | PTPRB (0.44) | ESR1ESR2PTPRBPPARGPPARD | |
| SCHEMBL5871568 | 0.72 | PTPRB (0.44) | ESR1ESR2PTPRBPPARGPPARD | |
| SCHEMBL6384666 | 0.71 | NLRP3 (0.51) | ESR1ESR2PTPRBPPARGPPARD | |
| SCHEMBL5872188 | 0.71 | PTPRB (0.43) | ESR1ESR2PTPRBPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | ESR1 3308/4885ESR2 1023/4885PTPRB 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.